Quantcast

Latest Visual acuity Stories

2011-02-22 07:00:00

TARRYTOWN, N.Y., Feb. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months. Regeneron's submission includes a...

5f786f72a134d68d13addc283bb984111
2011-01-31 13:32:17

On Monday, a federal expert panel backtracked on its 2004 recommendation to screen all kids younger than five years for poor vision, lazy eye and other eye conditions. According to the U.S. Preventive Services Task Force (USPSTF), healthy children between three and five years should still be tested at least once, but there is not enough evidence to recommend screening of all young toddlers. "There are harms associated with all screening tests," said Dr. Ned Calonge, chair of the USPSTF and...

4f4f197a9b0231ab661663bc7f5117071
2010-11-22 09:05:00

A Massachusetts-based company has been given Food and Drug Administration (FDA) approval to conduct a trial in which embryonic stem cells will be used to treat individuals suffering from an eye condition that can lead to blindness. Advanced Cell Technology (ACT), a biotechnology firm that specializes in regenerative medicine, will use the stem cells to treat individuals suffering from Stargardt's Macular Dystrophy, a degenerative condition that affects the part of the retina where incoming...

2010-11-21 23:00:00

TARRYTOWN, N.Y. and BERLIN, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every...

2010-11-17 05:00:00

SARATOGA, Calif., Nov. 17, 2010 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices, today announced the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), designed to improve vision in patients with end-stage age-related macular degeneration (AMD) is named "Best of What's New" 2010 by Popular Science magazine. VisionCare's first-of-kind telescope implant is integral to a new patient care program, CentraSight(TM), for treating...

2010-09-05 23:59:00

LEUVEN, Belgium, September 6, 2010 /PRNewswire-FirstCall/ -- - Data Presented at EURETINA Highlight the Attractive Characteristics of this Novel Potential Treatment Option for Retinal Disorders ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were...

2010-07-13 02:34:40

Among adolescents, visual acuity tests appear to reliably detect vision problems caused by nearsightedness but not farsightedness or astigmatism, according to a report in the July issue of Archives of Ophthalmology, one of the JAMA/Archives journals. Uncorrected refractive error"”a malfunction in the way the eye focuses light"”is the most common cause of reduced vision in children, according to background information in the article. Myopia (nearsightedness) and astigmatism...

2010-07-06 08:00:00

SARATOGA, Calif., July 6 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices, today announced the U.S. Food and Drug Administration (FDA) has approved the company's Implantable Miniature Telescope (by Dr. Isaac Lipshitz) to improve vision in patients with end-stage age-related macular degeneration (AMD). VisionCare's first-of-kind telescope implant is integral to a new patient care program, CentraSight, for treating patients with...

2010-06-17 06:00:00

MOUNTAIN VIEW, Calif., June 17 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced the recent publication of a clinical study comparing results obtained in the treatment of diabetic macular edema (DME) using an IRIDEX laser and MicroPulse(TM) treatment protocol to those obtained using the recognized standard of care Early Treatment of Diabetic Retinopathy Study (ETDRS) laser protocol. At one year, the prospective, randomized study demonstrated that a MicroPulse protocol...

2010-06-11 13:35:48

An inexpensive, but unlicensed drug to help prevent severe sight loss in older people has been shown to be safe and effective, finds a study published on bmj.com today. Bevacizumab (Avastin) is licensed as a treatment for bowel cancer, but it is widely used "off label" as a considerably cheaper alternative to the approved drug ranibizumab (Lucentis) to prevent wet age related macular degeneration (AMD) and several large trials comparing the two drugs are now underway. Although ranibizumab was...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.